Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FASTIN vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.
Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.
Short-term adjunct in exogenous obesity,Off-label: Attention deficit hyperactivity disorder (ADHD)
FDA-approved: Temporary relief of minor aches and pains (headache, muscle ache, toothache, backache, menstrual cramps), reduction of fever.,Off-label: None commonly accepted.
30 mg orally once daily in the morning, administered as a single dose.
1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.
Terminal elimination half-life is approximately 16-20 hours for the immediate-release formulation. With sustained-release forms, effective half-life may extend to 24-34 hours due to prolonged absorption. Clinical context: time to reach steady state is about 3-5 days.
Acetaminophen: 2-4 hours (prolonged in liver disease); aspirin: 15-20 minutes (active metabolite salicylate: 2-3 hours at low doses, prolonged to 15-30 hours at high doses); caffeine: 3-6 hours (prolonged in pregnancy, liver disease).
Hepatic metabolism via CYP3A4 and CYP2D6; active metabolite phendimetrazine (for some formulations).
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP2E1 (toxic metabolite NAPQI); Aspirin: hydrolyzed to salicylate, further metabolized by conjugation (glycine, glucuronic acid) and oxidation; Caffeine: hepatic via CYP1A2 (major), CYP2E1, CYP3A4, N-acetyltransferase.
Primarily renal (approximately 70-80% unchanged) and biliary/fecal (20-30% as metabolites). Urinary excretion is p H-dependent; acidic urine increases elimination.
Acetaminophen: renal elimination of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%, unchanged 2%); aspirin: renal elimination of salicylate and metabolites (75% salicyluric acid, 10% glucuronides, 10% salicylate); caffeine: renal elimination of metabolites (paraxanthine, theobromine, theophylline; <3% unchanged). Total: >95% renal.
Approximately 40-50% bound to plasma proteins (albumin).
Acetaminophen: 10-25% (albumin); aspirin: 80-90% (albumin, decreased at high doses); caffeine: 35% (albumin).
Approximately 3-5 L/kg. High Vd indicates extensive tissue distribution, including brain.
Acetaminophen: 0.9-1.0 L/kg; aspirin: 0.15-0.2 L/kg (low); caffeine: 0.6-0.8 L/kg. Reflects distribution into total body water.
Oral immediate-release: ~90% (high first-pass metabolism; absolute bioavailability is lower, but systemic exposure is adequate). Oral sustained-release: similar extent but with prolonged absorption.
Acetaminophen: oral 85-98%; aspirin: oral 50-80% (due to first-pass hydrolysis); caffeine: oral ~100%.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²), reduce dose to 15 mg once daily.
Contraindicated in severe renal impairment (Cr Cl <10 m L/min). For Cr Cl 10-50 m L/min: avoid aspirin component; consider alternative therapy. For Cr Cl >50 m L/min: no adjustment needed for acetaminophen; aspirin may require dose reduction or monitoring.
Contraindicated in Child-Pugh class C cirrhosis. In Child-Pugh class A or B, initiate at 15 mg once daily and titrate cautiously to maximum 30 mg once daily.
Child-Pugh A: caution with acetaminophen (max 2 g/day) and avoid caffeine if severe. Child-Pugh B: avoid aspirin; reduce acetaminophen dose (max 2 g/day) and limit caffeine. Child-Pugh C: contraindicated due to aspirin and acetaminophen risk.
Not recommended for pediatric patients under 16 years of age due to lack of safety and efficacy data.
Not recommended for children <12 years due to aspirin risk of Reye's syndrome. For adolescents ≥12 years: same as adult dosing: 1-2 tablets every 4-6 hours, max 8 tablets/24 hours.
Initiating at 15 mg once daily is recommended due to increased sensitivity and potential for central nervous system adverse effects; maximum dose 30 mg once daily.
Caution due to increased sensitivity to aspirin (GI bleeding, renal impairment) and caffeine (insomnia, tachycardia). Start at low end of dosing: 1 tablet every 6 hours; monitor renal function and avoid long-term use.
None.
Reye syndrome warning: Aspirin should not be used in children or teenagers with viral illnesses due to risk of Reye syndrome.
Cardiovascular events (hypertension, tachycardia, stroke), psychiatric adverse effects (psychosis, dependence), primary pulmonary hypertension, valvular heart disease, tolerance, withdrawal symptoms, glaucoma, hyperthyroidism, seizure disorder, diabetes (dose adjustment required), elderly patients (higher sensitivity).
Hepatotoxicity (acetaminophen overdose), gastrointestinal bleeding (aspirin), Reye syndrome (aspirin in children with viral illness), cardiovascular risk (aspirin may increase bleeding), caffeine-related CNS stimulation, risk of dependence.
Cardiovascular disease (e.g., coronary artery disease, arrhythmias, hypertension), hyperthyroidism, glaucoma, agitated states, history of drug abuse, MAOIs (concurrent or within 14 days), hypersensitivity to sympathomimetics.
Hypersensitivity to any component; active peptic ulcer disease; bleeding disorders; severe hepatic impairment; children/adolescents with viral illness (Reye syndrome); third trimester of pregnancy (aspirin); concurrent use of other salicylates or NSAIDs; severe renal impairment.
Avoid excessive caffeine intake (e.g., coffee, tea, cola, energy drinks) as it may potentiate CNS and cardiovascular effects. Grapefruit juice may alter drug metabolism; avoid concurrent consumption. Maintain a balanced, reduced-calorie diet as part of the weight loss plan. Alcohol should be avoided due to potential additive CNS effects.
Alcohol increases risk of hepatotoxicity with acetaminophen and GI bleeding with aspirin. Caffeine-containing foods or beverages should be limited to avoid excessive caffeine intake. High-tyramine foods (e.g., aged cheeses, cured meats) may potentiate caffeine effects; no significant interaction documented.
FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, low birth weight, and neonatal withdrawal syndrome. Avoid use in pregnancy.
First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible association with gastroschisis. Second trimester: Aspirin may increase risk of intracranial hemorrhage; acetaminophen and caffeine generally not linked to major malformations. Third trimester: Aspirin use is contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios; high-dose acetaminophen may cause oligohydramnios; caffeine metabolism slows, but moderate intake appears safe; chronic high-dose caffeine may be associated with low birth weight.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infants (irritability, poor feeding). Contraindicated during breastfeeding.
Acetaminophen: M/P ratio approximately 0.9; small amounts excreted; considered safe. Aspirin: M/P ratio variable, typically 0.12-0.42; avoid high doses due to risk of Reye's syndrome; single doses unlikely harmful. Caffeine: M/P ratio approximately 0.5-1.0; moderate intake (≤300 mg/day) considered safe; excessive intake may cause irritability in infant.
Contraindicated in pregnancy; no dose adjustments recommended.
Acetaminophen: No dose adjustment needed; standard dosing (650-1000 mg every 4-6 hours, max 3000 mg/day). Aspirin: Avoid doses >81 mg/day in third trimester; use lowest effective dose. Caffeine: Metabolism prolonged; limit to ≤200 mg/day (approximately 2 cups coffee).
Fastin (phentermine) is a sympathomimetic amine indicated for short-term (up to 12 weeks) monotherapy for obesity. It should be used in conjunction with a reduced-calorie diet and exercise. Avoid co-administration with MAOIs or within 14 days of MAOI use due to hypertensive crisis risk. Use with caution in patients with hypertension, diabetes, or history of drug abuse. Monitor blood pressure and heart rate regularly. Tachyphylaxis may develop; discontinue if tolerance occurs. Do not use in patients with advanced arteriosclerosis, hyperthyroidism, glaucoma, or agitated states.
Acetaminophen, aspirin, and caffeine combination is used for mild to moderate pain and fever reduction. Aspirin component provides anti-inflammatory effects; caution in patients with bleeding disorders or those on anticoagulants due to increased bleeding risk. Acetaminophen hepatotoxicity risk with doses >4g/day or in liver disease. Caffeine may cause insomnia, tremor, or palpitations; avoid in patients with anxiety disorders. Reye syndrome risk with aspirin use in children with viral illnesses. Monitor renal function in elderly or dehydrated patients.
Take Fastin exactly as prescribed, usually once daily in the morning to avoid insomnia.,Do not crush or chew the extended-release capsule; swallow whole.,Avoid taking late in the day to prevent difficulty sleeping.,Report any chest pain, palpitations, shortness of breath, or dizziness immediately.,Do not increase dose or take more frequently than prescribed; risk of dependence and side effects.,Fastin is for short-term use only (up to 12 weeks) and should be combined with a reduced-calorie diet and exercise.,Do not use if you have taken an MAO inhibitor in the last 14 days.,Avoid alcohol and other CNS stimulants (e.g., caffeine in large amounts) as they may increase side effects.,Do not stop abruptly; follow your doctor's instructions for tapering off.,Keep out of reach of children; misuse can cause severe cardiac toxicity.
Do not exceed recommended dose; acetaminophen overdose can cause liver damage.,Avoid alcohol while taking this medication.,Do not use in children or teenagers with viral illnesses due to Reye syndrome risk.,May cause stomach upset; take with food or milk.,Limit caffeine intake from other sources when using this medication.
No interactions on record
"Triamterene, a potassium-sparing diuretic, can inhibit the hepatic metabolism of caffeine by competing for cytochrome P450 (CYP) 1A2, the primary enzyme responsible for caffeine clearance. This leads to increased plasma caffeine concentrations and prolonged caffeine half-life, potentially causing caffeine toxicity manifesting as nervousness, insomnia, tachycardia, and diuresis enhancement. Patients may experience exaggerated stimulant effects and increased risk of cardiac arrhythmias when combining these agents."
"Caffeine inhibits the metabolism of sulfadiazine by competitively antagonizing cytochrome P450 (CYP) enzymes, particularly CYP1A2, leading to increased plasma concentrations of sulfadiazine. This elevates the risk of dose-dependent adverse effects, including crystalluria, nephrotoxicity, and hypersensitivity reactions. The interaction may also reduce the therapeutic efficacy of sulfadiazine due to altered pharmacokinetics."
"Caffeine inhibits the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of losartan to its active metabolite E-3174. This inhibition can lead to increased plasma concentrations of losartan and decreased formation of the active metabolite, potentially reducing losartan's antihypertensive efficacy. The clinical outcome may be suboptimal blood pressure control in patients consuming high amounts of caffeine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FASTIN vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE, answered by our medical review team.
FASTIN is a Sympathomimetic Anorectic that works by Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is a NSAID / Antiplatelet that works by Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FASTIN and ACETAMINOPHEN, ASPIRIN AND CAFFEINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FASTIN is: 30 mg orally once daily in the morning, administered as a single dose.. The standard adult dose of ACETAMINOPHEN, ASPIRIN AND CAFFEINE is: 1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FASTIN and ACETAMINOPHEN, ASPIRIN AND CAFFEINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FASTIN is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, lo. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is classified as Category D/X. First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.